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These ﬁndings suggest that host T cells are elicited following
direct recognition of—and co-stimulation by—donor APC. To
address this hypothesis, CD80/86/ mice were transplanted with
C3H.SW BM. Rejection was efﬁcient and equivalent to that in
B6-wt mice. These ﬁndings support the notion that CD80/86
co-stimulation by donor APC’s is sufﬁcient and required to initiate
resistance against donor BM in “naı¨ve” recipients. In contrast,
recipients sensitized to B6 antigens prior to transplant rejected
both B6-wt and CD80/86/ grafts with equal and accelerated
kinetics vs. “naı¨ve” recipients. These observations suggest that B7
co-stimulation is not required to elicit effectors from TM and/or
that indirect presentation could be occurring. To begin examining
CD80/86 expression on donor APC as a potential strategy for
tolerance induction, C3H.SW BMT recipients received a second
transplant of B6 Ly5.1 or B6-gfp TCD-BM. Although prior re-
cipients of B6-wt marrow rejected these second B6 transplants with
accelerated kinetics, prior recipients of CD80/86/ BM rapidly
achieved and maintained multi-lineage Ly5.1 or gfp chimerism.
In total, these results support the notion that in non-myeloablative
MHC-matched allogeneic BMT, donor APC are critical to initi-
ating the T cell barrier response to engraftment. Moreover, the
absence of CD80/86 co-stimulatory molecules on donor APC can
apparently circumvent T cell mediated resistance and may provide
a strategy for the rapid tolerance induction in such transplants.
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LACK OF IMPACT OF COMORBIDITIES ON OUTCOMES OF ALLOGENEIC
STEM CELL TRANSPLANTATION (ASCT) FOR REFRACTORY ACUTE MY-
ELOID LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Wong, R.S.; Shahjahan, M.; Alamo, J.; de Lima, M.; Khouri, I.;
Gajewski, J.; Andersson, B.; Champlin, R.; Giralt, S. University of
Texas M. D. Anderson Cancer Center, Houston, TX.
Introduction: Comorbidities may have impact on both survival
and treatment toxicities in several types of malignancies. We have
previously demonstrated that patients with comorbidities have
lower overall and event free survival (OS/EFS) as well as higher
non-relapse mortality (NRM) in patients with AML/MDS patients
in ﬁrst complete remission undergoing ASCT. However, other
studies suggested that concurrent comorbidities have less impact in
groups with the lowest survival rate. We study the impact of
comorbidities on outcomes in patients receiving ASCT for refrac-
tory AML/MDS. Methods: We retrospectively reviewed 135 pa-
tients with refractory AML (n93), MDS (n24) and MDS/AML
(n18) who received ASCT between 1/1998 and 2/2001 at the
University of Texas M.D. Anderson Cancer Center. Charlson
Comorbidity Index (CCI) was used to score comorbid conditions
and CCI score was calculated for each patient as a weighted score
of the patient’s total comorbid conditions. Results: Median age
was 49 years (range 19–75). There were 77 males and 58 females.
Disease status included primary induction failure (n53), ﬁrst
relapse refractory diseases (n49) and patients with more than two
relapses (n33). 55 patients received myeloablative conditioning
regimens including Thiotepa/BU/CY (n29), BU/CY (n19) and
TBI (N7). 80 patients received reduced intensity conditioning
regimens with F-Ara-Ida (n16), FM	 ATG (n43) and F/BU	
ATG or CAMPATH-1H (n21). Analysis was performed com-
paring patients with a CCI score of 0, 1–2 and 2. Univariate
analysis showed that patients with CCI scores of 1–2 and 2 had
no statistically signiﬁcant difference in the overall and event free
survival (OS/EFS) as well as non-relapse mortality (NRM) com-
pared with patients who had a score of 0 (Table 1). Conclusions:
Our results demonstrate that comorbidities have little impact on
the outcomes of patients with refractory AML/MDS. In these
patients, the primary disease, rather than other concurrent dis-
eases, primarily determines survival. Our ﬁndings suggest these
patients can be included in ASCT protocols even if they have
comorbidities. Improvement in disease-speciﬁc survival will trans-
late into improvements in overall survival regardless of coexisting
disease.
Effect of Comorbidity Scores on Allogeneic Transplant Outcomes in
AML/MDS Patients
Outcomes
CCI
Score  0
(N  59)
CCI
Score 1–2
(N  58)
CCI
Score > 2
(N  18)
% OS at 2 years 24 16 39
% EFS at 2 years 20 13 39
% NRM at 1 year 39 52 33
No statistically signiﬁcant difference found in patients with CCI
scores of 1–2 and  2 compared with patients with a score of 0.
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ONCE DAILY INTRAVENOUS (IV) BUSULFAN (BU) CONTAINING PRE-
PARATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): LOW INCIDENCE OF HEPATIC VENO-OCCLUSIVE DIS-
EASE (HVOD) AND IMPROVED EARLY SURVIVAL IN A SINGLE CENTER’S
EXPERIENCE
Benn, H.; Amin, A.; Susan, H.-C.; Kramek, D.; Janbay, N.;
Randhawa, D.; Nath, R. Saint Joseph’s Regional Medical Center, Pater-
son, NJ.
Background: IV Bu has demonstrated similar outcomes but
lower incidence of HVOD when used instead of oral Bu as a
component of preparative regimens for HSCT. The usual dose for
IV Bu is 0.8 mg/kg q 6 h. Once daily IV Bu (3.2 mg/kg/day) has
been successfully combined with Fludarabine in HSCT. There are
very limited and conﬂicting data about the safety of combining
once daily IV Bu with other chemotherapeutic drugs in preparative
regimens. Patients and Methods: Twenty one patients with he-
matological malignancies were identiﬁed in our database who had
undergone once daily IV Bu containing preparative regimens for
HSCT between June 2002 and September 2004. There were 15
males and 6 females. Their median age was 48 (range 19–62) years.
Preparative regimens were as follows: Thiotepa 10 mg/kg/day 1,
Bu 3.2 mg/kg/day  3, Cyclophosphamide (CY) 60 mg/kg/day 
2 for 11 patients; Bu 3.2 mg/kg/day 4, CY 60 mg/kg/day 2 for
7 patients; and Bu 3.2 mg/kg/day  4, Etoposide 60 mg/kg/day 
1 for 3 patients. Sixteen patients underwent allogeneic SCT (un-
related cord blood n10, matched sibling n6) and 4 patients
underwent autologous SCT. GVHD prophylaxis consisted of Ta-
crolimus/Mycophenolate Mofetil (MMF)/Antithymocyte globulin
(ATG) in 10 patients, Cyclosporine A (CsA)/Methotrexate in 5,
and CsA/MMF/ATG in 2 patients. All patients received Ursode-
oxycholic acid and Enoxaparin for prophylaxis of HVOD. Three
patients had undergone a prior SCT (mini allogeneic n2; autol-
ogous n1). Four patients had a history of abnormal liver function
tests. Eleven patients had active disease at the time of HSCT and
4 patients were in  second complete remission. Results: All 20
evaluable patients engrafted with a median time for neutrophil
recovery of 18 (range 9–32) days. One patient died prior to HSCT
because of cardiac toxicity. Seven patients (35%) developed hyper-
bilirubinemia (bilirubin 2 mg/dl) within the ﬁrst 30 days and ten
patients (50%) developed hyperbilirubinemia within ﬁrst 100 days
post transplant with the peak bilirubin being 4.0 and 7.1 mg/dl
respectively. Two patients (10%) had mild HVOD based on the
modiﬁed Seattle Criteria which resolved without any intervention.
Eighteen of the nineteen evaluable patients (94.7%) were surviving
on day 100. Conclusion: Preparative regimens combining once
daily IV Bu along with other alkylating agents or etoposide result
in universal engraftment, a low incidence of HVOD and excellent
early survival.
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LONG-TERM FOLLOW UP OF PATIENTS WHO EXPERIENCED GRAFT
FAILURE POST ALLOGENEIC PROGENITOR CELL TRANSPLANTATION
Rondon, G.; Khouri, I.; Giralt, S.; Chan, K.; McMannis, J.; Champlin,
R.; Shpall, E. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
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